Cart
sales@molnova.com
Home -
Products -
Others -
Other Targets -
[Tyr0] Gastric Inhibitory Peptide (23-42), human; [Tyr22] Gastric Inhibitory Peptide (22-42), human
[Tyr0] Gastric Inhibitory Peptide (23-42), human; [Tyr22] Gastric Inhibitory Peptide (22-42), human
CAS No. ———
[Tyr0] Gastric Inhibitory Peptide (23-42), human; [Tyr22] Gastric Inhibitory Peptide (22-42), human( ——— )
Catalog No. M41205 CAS No. ———
[Tyr0] Gastric Inhibitory Peptide (23-42), human; [Tyr22] Gastric Inhibitory Peptide (22-42), human
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name[Tyr0] Gastric Inhibitory Peptide (23-42), human; [Tyr22] Gastric Inhibitory Peptide (22-42), human
-
NoteResearch use only, not for human use.
-
Brief Description[Tyr0] Gastric Inhibitory Peptide (23-42), human; [Tyr22] Gastric Inhibitory Peptide (22-42), human
-
Description[Tyr0] Gastric Inhibitory Peptide (23-42), human; [Tyr22] Gastric Inhibitory Peptide (22-42), human
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number———
-
Formula Weight2584.9
-
Molecular FormulaC119H182N34O31
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Benzododecinium chlo...
Benzyldimethyldodecylammonium chloride is a quaternary ammonium compound.Benzododecinium chloride is an irritant for eye.
-
Wilforol A
Wilforol A ((-)-Wilforol A), plant metabolite, is a pentacyclic triterpenoid. Wilforol A can be used for the research of various biochemical studies.
-
Isoviolanthin
Isoviolanthin reduces the migratory and invasive capacities of TGF-β1-treated HCC cells but exhibits no cytotoxic effects on normal live cells, and has potential as a therapeutic agent for the treatment of advanced-stage metastatic HCC.
